Skip to main content

Crysvita Disease Interactions

There are 3 disease interactions with Crysvita (burosumab).

Major

Burosumab (applies to Crysvita) hyperphosphatemia

Major Potential Hazard, Moderate plausibility. Applicable conditions: Phosphate Imbalance

Do not initiate burosumab-twza treatment if serum phosphorus is within or above the normal range for age. Increases in serum phosphorus to above the upper limit of normal may be associated with an increased risk of nephrocalcinosis. It is recommended to obtain baseline fasting serum phosphorus levels and to monitor fasting serum phosphorus levels. Dose interruption and/or dose reduction may be required based on a patient's serum phosphorus levels.

References

  1. "Product Information. Crysvita (burosumab)." Ultragenyx Pharmaceutical (2018):
Major

Burosumab (applies to Crysvita) renal impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Burosumab-twza is contraindicated in patients with severe renal impairment or end stage renal disease because these conditions are associated with abnormal mineral metabolism. The effect of renal impairment on the pharmacokinetics of burosumab-twza is unknown.

References

  1. "Product Information. Crysvita (burosumab)." Ultragenyx Pharmaceutical (2018):
Moderate

Burosumab (applies to Crysvita) RLS

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Neurologic Disorder

The use of burosumab-twza may cause new onset of restless leg syndrome (RLS) or worsen RLS severity. Care should be exercised when using this agent in patients with existing RLS diagnosis.

References

  1. "Product Information. Crysvita (burosumab)." Ultragenyx Pharmaceutical (2018):

Crysvita drug interactions

There are 16 drug interactions with Crysvita (burosumab).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer